Vitazi-DR™
Vitazi-DR™ is a cutting-edge, autonomous diabetic retinopathy (DR) detection solution designed to significantly accelerate the diagnosis process, delivering results in less than 45 seconds. Currently, Vitazi-DR is undergoing clinical trials for FDA 510(k) clearance and is not yet FDA-approved for use in the United States.
Despite this, Vitazi-DR has already achieved impressive results internationally. At Clinicas del Azucar™—a leading network of diabetes care clinics in Monterrey, Mexico—Vitazi-DR has been implemented with over
95% accuracy. Vitazi.ai, Inc. has studied over 150,000 cases internally, underscoring its effectiveness in real-world settings.
Clinicas del Azucar provides a comprehensive, turnkey solution for diabetic care, and Vitazi.ai is proud to partner with them in their mission to enhance the lives of people with diabetes. By integrating Vitazi-DR into their services, Clinicas del Azucar continues to offer patients rapid, reliable diabetic retinopathy screenings with unprecedented efficiency.
Autonomous Diabetic Retinopathy Detection in Under 45 Seconds
The Growing Global Demand for Diabetic Retinopathy Screening Solutions
The need for diabetic retinopathy (DR) screening is rising rapidly across the globe, driven by changing dietary habits and decreasing levels of physical activity. As a result, up to 30% of diabetics worldwide are at risk of vision loss or blindness without proper screening solutions like Vitazi-DR.
While Vitazi-MD™ serves patients in the U.S., the limited number of board-certified ophthalmologists hinders international scalability. However, the introduction of Vitazi-DR—an AI-powered diagnostic solution—opens up new
possibilities for global diabetic retinopathy screening. With high accuracy, cost-effectiveness, and unlimited scalability, Vitazi-DR offers an unparalleled solution to combat DR worldwide.
This revolutionary technology holds the potential to save millions from the devastating impact of diabetic retinopathy, offering efficient and accessible screening on a global scale.
Find out more about Vitazi-DR or diabetic retinopathy challenges
